Sat, Feb 28, 2015, 2:55 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • mtaotter mtaotter Apr 25, 2013 5:37 PM Flag

    Herceptin subcutaneous is not being reviewed by CHMP this month -- not on calendar.

    Kadacyla is being reviewed, which is a herceptin combination drug. That drug is very toxic and comes with a black box warning in the U.S. when it was passed by the FDA earlier this year.

    I think we are waiting on HYQvia European Commission confirmation of CHMP validation back in March. I think the Mab Thera competitor failure is probably too bad for patients but good for Roche and likely Halozyme.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
15.07-0.21(-1.37%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.